CG Oncology, Inc. reported $6.2M of revenue over the trailing twelve months, +1030% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $6.2M (to Q2 2026). Net income: −$224M, trailing twelve months to Q2 2026. Free cash flow: −$179M, trailing twelve months to Q2 2026. Operating margin: −4691%, trailing twelve months to Q2 2026.

CGONCG Oncology, Inc.

Healthcare

$63.86+73% 1Y

$63.86

$36.4852 weeks$80.66

CGON as reported

CG Oncology, Inc. reported $6.2M of revenue over the trailing twelve months, +1030% on the year before. 9 reported series are charted on this page, each one as filed.

$6.2M

Revenue, trailing twelve months · to Q2 2026 · +1030% against the twelve months before

Net income: −$224M
Net income · +75% year on year · trailing twelve months to Q2 2026
Free cash flow: −$179M
Free cash flow · +91% year on year · trailing twelve months to Q2 2026
Operating margin: −4691%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CGON, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$6.2M	+1030%	Q2 2026
Net income	−$224M	+75%	Q2 2026
EPS	−$2.69	+52%	Q2 2026
Operating margin	−4691%	n/a	Q2 2026
Net margin	−4200%	n/a	Q2 2026
ROE	−21%	n/a	Q2 2026
ROA	−20%	n/a	Q2 2026
ROIC	−2151%	n/a	Q2 2026
Free cash flow	−$179M	+91%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.